BIOAClinical Trials•globenewswire•
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
Sentiment:Neutral (45)
Summary
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 15, 2025 by globenewswire